ICD-10-PCS Codes

• 1 XW01318 (INTRODUCTION OF DARATUMUMAB AND HYALURONIDASE-FIHJ INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 2 XW01329 (INTRODUCTION OF TALQUETAMAB ANTINEOPLASTIC INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 3 XW01348 (INTRODUCTION OF TECLISTAMAB ANTINEOPLASTIC INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 8)

• 4 XW0136A (INTRODUCTION OF DASIGLUCAGON INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 10)

• 5 XW01397 (INTRODUCTION OF SATRALIZUMAB-MWGE INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 6 XW013F5 (INTRODUCTION OF OTHER NEW TECHNOLOGY THERAPEUTIC SUBSTANCE INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 7 XW013G6 (INTRODUCTION OF REGN-COV2 MONOCLONAL ANTIBODY INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 8 XW013H6 (INTRODUCTION OF OTHER NEW TECHNOLOGY MONOCLONAL ANTIBODY INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 9 XW013K6 (INTRODUCTION OF LERONLIMAB MONOCLONAL ANTIBODY INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 10 XW013L9 (INTRODUCTION OF ELRANATAMAB ANTINEOPLASTIC INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 11 XW013S6 (INTRODUCTION OF COVID-19 VACCINE DOSE 1 INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 12 XW013S9 (INTRODUCTION OF EPCORITAMAB MONOCLONAL ANTIBODY INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 9)

• 13 XW013T6 (INTRODUCTION OF COVID-19 VACCINE DOSE 2 INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 14 XW013TB (INTRODUCTION OF ROZANOLIXIZUMAB-NOLI MONOCLONAL ANTIBODY INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 11)

• 15 XW013U6 (INTRODUCTION OF COVID-19 VACCINE INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 6)

• 16 XW013V7 (INTRODUCTION OF COVID-19 VACCINE DOSE 3 INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 17 XW013W5 (INTRODUCTION OF CAPLACIZUMAB INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 5)

• 18 XW013W7 (INTRODUCTION OF COVID-19 VACCINE BOOSTER INTO SUBCUTANEOUS TISSUE, PERCUTANEOUS APPROACH, NEW TECHNOLOGY GROUP 7)

• 19 XW01X27 (INTRODUCTION OF ANACAULASE-BCDB INTO SUBCUTANEOUS TISSUE, EXTERNAL APPROACH, NEW TECHNOLOGY GROUP 7)